Literature DB >> 26668347

Using Minimal Residual Disease to Improve Treatment Response Definitions and Hematopoietic Cell Transplantation Strategy in Acute Leukemia.

Renato Bassan1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26668347     DOI： 10.1200/JCO.2015.64.8907

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Recommendations for reporting post-transplant relapse in AML.

Authors:  A Rashidi; M A Linden; M-E Percival; B M Sandmaier; S Devine; D J Weisdorf
Journal:  Bone Marrow Transplant       Date:  2017-10-30       Impact factor: 5.483

Review 2.  Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.

Authors:  P Tsirigotis; M Byrne; C Schmid; F Baron; F Ciceri; J Esteve; N C Gorin; S Giebel; M Mohty; B N Savani; A Nagler
Journal:  Bone Marrow Transplant       Date:  2016-06-13       Impact factor: 5.483

3.  Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.

Authors:  Sylvie D Freeman; Robert K Hills; Paul Virgo; Naeem Khan; Steve Couzens; Richard Dillon; Amanda Gilkes; Laura Upton; Ove Juul Nielsen; James D Cavenagh; Gail Jones; Asim Khwaja; Paul Cahalin; Ian Thomas; David Grimwade; Alan K Burnett; Nigel H Russell
Journal:  J Clin Oncol       Date:  2018-03-30       Impact factor: 44.544

4.  Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients.

Authors:  Bianca R Schnell; Katja Seipel; Ulrike Bacher; Barbara Jeker; Beatrice U Mueller; Yara Banz; Urban Novak; Thomas Pabst
Journal:  Hemasphere       Date:  2019-03-20

5.  Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia.

Authors:  Tali Azenkot; Brian A Jonas
Journal:  Cancers (Basel)       Date:  2022-07-26       Impact factor: 6.575
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.